| Date | Title | |
| 11/19/09 | ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Company's TAP Technology |  |
| 11/17/09 | ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma | |
| 11/11/09 | ImmunoGen, Inc. Announces Election of Howard Pien to its Board of Directors and Other Results from its Annual Meeting of Shareholders | |
| 11/10/09 | ImmunoGen, Inc. Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | |
| 10/29/09 | ImmunoGen, Inc. Reports First Quarter Fiscal Year 2010 Financial Results | |
| 10/27/09 | ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 20th Annual Healthcare Conference | |
| 10/22/09 | ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2010 Financial Results | |
| 09/16/09 | ImmunoGen Announces Amgen has Licensed Rights to Use the Company's TAP Technology for a Solid Tumor Target | |
| 09/02/09 | ImmunoGen, Inc. Announces Webcast of Presentations at Two Investor Conferences | |
| 08/17/09 | ImmunoGen, Inc. Appoints Peter Williams as Vice President, Business Development | |
| 08/06/09 | ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2009 Financial Results | |
| 08/05/09 | ImmunoGen, Inc. Announces Webcast of Presentation at the 29th Annual Canaccord Adams Global Growth Conference | |
| 07/31/09 | ImmunoGen Announces Encouraging New Clinical Data with the Company's IMGN901 Compound in the Treatment of Small-Cell Lung Cancer | |
| 07/30/09 | ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2009 Financial Results | |
| 06/23/09 | ImmunoGen, Inc. Announces Completion of Public Offering of Common Stock | |
| 06/22/09 | ImmunoGen, Inc. Announces Exercise of Over-allotment Option | |
| 06/18/09 | ImmunoGen, Inc. Prices Public Offering of Common Stock | |
| 06/17/09 | ImmunoGen, Inc. Announces Proposed Public Offering of Common Stock | |
| 06/11/09 | ImmunoGen, Inc. Elects to Discontinue Further Internal Development of Its IMGN242 Compound | |
| 05/30/09 | ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented at ASCO | |
| 05/14/09 | ImmunoGen, Inc. Announces Trastuzumab-DM1 Presentations at the 2009 American Society for Clinical Oncology Annual Meeting | |
| 04/30/09 | ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2009 Financial Results | |
| 04/23/09 | ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2009 Financial Results | |
| 04/10/09 | ImmunoGen, Inc. Announces Presentations at the American Association for Cancer Research Annual Meeting | |
| 03/03/09 | ImmunoGen, Inc. Announces Webcast of Presentation at the Barclays Capital Global Healthcare Conference | |
| 03/02/09 | ImmunoGen, Inc. Earns Milestone Payment with Genentech's Start of Trastuzumab-DM1 (T-DM1) Phase III Clinical Testing; Other T-DM1 Progress Reported | |
| 02/02/09 | ImmunoGen, Inc. Announces Webcast of Presentation at the BIO CEO & Investor Conference 2009 | |
| 01/29/09 | ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2009 Financial Results | |
| 01/28/09 | ImmunoGen, Inc. Announces Webcast of its Investment Community Meeting on February 27, 2009 | |
| 01/22/09 | ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2009 Financial Results | |
| 01/09/09 | ImmunoGen, Inc. Appoints Gregory Perry as Senior Vice President and Chief Financial Officer | |
| 01/08/09 | ImmunoGen, Inc. Announces Webcast of Presentation at the 27th Annual J.P. Morgan Healthcare Conference | |
